GlassScriptPhysician profile
John E Rathbun
NPI 1558345686
$6,711.57
in general payments reported to CMS, 2019-2025
41 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $1,531 · 2021: $1,445 · 2022: $698 · 2023: $568 · 2024: $777 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,036.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $936.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $540.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $527.46 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $503.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $445.30 | 2019-2025 | |
| Pfizer INC. | $436.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $382.54 | 2022-2025 | |
| Novo Nordisk INC | $295.31 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $264.08 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $262.71 | 2020-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.62 | 2019-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $171.97 | 2020-2023 | Seglentis, Livalo |
| E.R. Squibb & Sons, L.L.C. | $166.47 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $155.96 | 2019-2025 | |
| Lilly USA, LLC | $148.95 | 2020-2025 | Mounjaro |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $124.42 | 2020-2024 | Injectafer |
| Astellas Pharma US INC | $121.54 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $115.33 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $112.92 | 2019-2021 | |
| Mylan Specialty L.P. | $76.58 | 2020-2024 | Yupelri |
| Amgen INC. | $71.54 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $71.00 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.72 | 2019-2021 | |
| Eisai INC. | $48.02 | 2021-2022 | |
| Dexcom, INC. | $46.22 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $41.48 | 2021-2022 | |
| Exact Sciences Corporation | $37.67 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $37.29 | 2021-2022 | |
| Zyla Life Sciences, INC. | $30.59 | 2019 | |
| Horizon Therapeutics Plc | $29.76 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.73 | 2022 | |
| Nevro Corp. | $27.33 | 2023 | Senza |
| Celgene Corporation | $23.70 | 2019 | |
| Corcept Therapeutics | $20.17 | 2025 | Korlym |
| Philips North America LLC | $19.80 | 2025 | Ecc Solutions |
| Biohaven Pharmaceutical Holding Company LTD. | $18.42 | 2022 | |
| Cvrx, INC. | $17.50 | 2024 | Barostim Neo System |
| Renalytix Ai, INC. | $16.43 | 2022 | |
| Viatris Specialty LLC | $14.72 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $13.77 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $13.37 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rathbun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.